|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 29, 2013 ) New York, NY -- A key collaborative effort announced in an 8-k filing by TrovaGene Inc (NASDAQ: TROV) last week could have a positive and profound impact on the future of the company, according to a Monday report by VFC's Stock House.
TrovaGene's share price started to spike late last year as the company's pipeline of diagnostics reached the commercial stages and recent collaborative efforts, included last week's with PerkinElmer Health Sciences Inc (NYSE: PKI), indicates that big players in the healthcare industry are quickly becoming believers in the technology.
The first of many potential share price and milestone catalysts came to fruition earlier this year when TrovaGene announced that it had commercially launched a urine-based human papillomavirus (HPV) diagnostic test, the first of numerous elements of its pipeline expected to hit market this year and a move into a very lucrative market, as six million new cases of HPV are diagnosed in the United States each year, according to the Centers for Disease Control and Prevention.
TrovaGene's technology utilizes transrenal DNA and RNA from simple urine samples to detect genetic abnormalities that may result from cell deaths and/or disease progression. Any diagnostic test resulting from the advancement of this technology follows the current healthcare industry trends of emphasizing early detection through less-invasive (and less costly) means and launching its first test onto the market is a huge validation to the company and its future prospects.
That said, the development and commercialization of such next-generation technology may not be enough alone to convince investors looking at the near term that the medical community is ready to fully embrace such a drastic shift in early-detection methods, but investors could quickly become convinced if much larger and more relevant parties from the industry come into play to support future development, such as that revealed regarding PerkinElmer last week.
A full version of this report is available by visiting: http://VFCsStockHouse.com
Disclosure: No position.
Follow the developments of these and other small cap stocks at VFCsStockHouse.com
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
Follow VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com: VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, small cap stocks and developmental companies of the healthcare sector. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. The information contained within the words of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
